› 5x02

X-ray diffraction
2.4Å resolution

Crystal structure of the FLT3 kinase domain bound to the inhibitor FF-10101

Released:
DOI: 10.2210/pdb5x02/pdb
PDB entry 5x02 coloured by chain, front view.
PDB entry 5x02 coloured by chain, side view.
PDB entry 5x02 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.
Yamaura T, Nakatani T, Uda K, Ogura H, Shin W, Kurokawa N, Saito K, Fujikawa N, Date T, Takasaki M, Terada D, Hirai A, Akashi A, Chen F, Adachi Y, Ishikawa Y, Hayakawa F, Hagiwara S, Naoe T, Kiyoi H
Blood 131 426-438 (2018)
PMID: 29187377

Function and Biology Details

Reaction catalysed: 
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-153242 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Receptor-type tyrosine-protein kinase FLT3 Chain: A
Molecule details ›
Chain: A
Length: 347 amino acids
Theoretical weight: 40.01 KDa
Source organism: Homo sapiens
Expression system: Spodoptera frugiperda
UniProt:
  • Canonical: P36888 (Residues: 564-958; Coverage: 36%)
Gene names: CD135, FLK2, FLT3, STK1
Sequence domains: Protein tyrosine and serine/threonine kinase
Structure domains:

Ligands and Environments

2 bound ligands:
Ligand F6M 1 x F6M
Ligand SO4 3 x SO4
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: PHOTON FACTORY BEAMLINE BL-17A
Spacegroup: P43212
Unit cell:
a: 81.993Å b: 81.993Å c: 143.558Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.236 0.234 0.277
Expression system: Spodoptera frugiperda

Quick links

Citations

26 review citations

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong et al. (2021)
25 more

7 mentions without citation

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.
Acharya et al. (2022)
6 more